Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy

BACKGROUND: Whether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and clinical outcomes, remains unknown. The objective of the current study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Truby, Lauren K., Regan, Jessica A., Giamberardino, Stephanie N., Ilkayeva, Olga, Bain, James, Newgard, Christopher B., O’Connor, Christopher M., Felker, G. Michael, Kraus, William E., McGarrah, Robert W., Shah, Svati H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336082/
https://www.ncbi.nlm.nih.gov/pubmed/34344360
http://dx.doi.org/10.1186/s12933-021-01353-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336082/
https://www.ncbi.nlm.nih.gov/pubmed/34344360
http://dx.doi.org/10.1186/s12933-021-01353-z

Ejemplares similares